NeuroStar® TMS Therapy
FDA-cleared, non-medication depression treatment
Existing Patients For Providers →
(855) 940-4867
Greenbrook is proud to sponsor Out Of The Darkness walks, the signature event of the American Foundation for Suicide Prevention, in cities throughout our regions from March to November.
Greenbrook is proud to sponsor Out Of The Darkness walks, the signature event of the American Foundation for Suicide Prevention, in cities throughout our regions from March to November. These virtual community walks aim to bring awareness to the high rate of suicide in the U.S., provide support and comfort to those affected by suicide, and raise funds for research and education about mental illnesses that lead to suicide. With suicide the second highest cause of death for ages 15-44 in America, events like Out of the Darkness walks are crucial to offer solutions to those who have lost hope.
Greenbrook will join the communities we support for this crucial cause and be part of the work to destigmatize mental illness. The U.S. Department of Health and Human Services (HHS) estimates that nearly 60% of those who die from suicide have suffered major depressive disorder (MDD) or another mood disorder. Because of this, identifying and treating patients with MDD is critically important in the effort to prevent suicide.
We invite you to join us to support the American Foundation for Suicide Prevention’s cause in a city near you! Whether you are attending a walk, walking in your own neighborhood, or participating virtually. For more information about Out Of The Darkness or the event, click on the event name below:
Saturday, September 26, 2020 @ 10am
Saturday, September 26, 2020
Saturday, September 26, 2020
Sunday, September 27, 2020 @ 11am
OCTOBER
Saturday, October 3, 2020
Sunday, October 17, 2020 @ 10am
NOVEMBER
Saturday, November 7, 2020 @ 10am
Saturday, November 7, 2020 @ 10am
Sunday, November 7, 2020 @ 12pm
Saturday, November 7, 2020 @ 12pm
Take our short quiz to see if TMS therapy or nasal esketamine could be right for you
Subscribe for mental health, self-care, and TMS therapy and nasal esketamine updates for those affected by treatment-resistant depression or OCD.
Thank you for subscribing to our email list!
Oops, there was an error adding your subscription.
Please try again later.
By providing your email address, you are consenting to receive blog updates from Greenbrook TMS Inc. You may unsubscribe from these alerts at any time by following the “unsubscribe” link at the bottom of email alerts. At Greenbrook TMS Inc. we take the privacy and security of your personal information seriously. To learn more about how we protect your personal information, please refer to our Privacy Policy.
Greenbrook supports an accessible internet. If you have any questions about our accessibility features, please contact us at
(855) 940-4867 or info@greenbrooktms.com.
NeuroStar Adult Indications for Use
The NeuroStar Advanced Therapy System is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from Major Depressive Disorder (MDD) and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode.
The NeuroStar Advanced Therapy System is intended to be used as an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD).
NeuroStar Adolescent Indications for Use
NeuroStar Advanced Therapy is indicated as an adjunct for the treatment of Major Depressive Disorder (MDD) in adolescent patients (15-21).
Important Safety Information
NeuroStar Advanced Therapy is only available by prescription. A doctor can help decide if NeuroStar Advanced Therapy is right for you. Patients’ results may vary.
The most common side effect is pain or discomfort at or near the treatment site. These events are transient; they occur during the TMS treatment course and do not occur for most patients after the first week of treatment. There is a rare risk of seizure associated with the use of TMS therapy (<0.1% per patient).
Visit neurostar.com for full safety and prescribing information.
Important Safety Information
What is the most important information I should know about SPRAVATO®?
SPRAVATO® can cause serious side effects, including:
Do not take SPRAVATO® if you:
If you are not sure if you have any of the above conditions, talk to your healthcare provider before taking SPRAVATO®.
Before you take SPRAVATO®, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines that you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Taking SPRAVATO® with certain medicine may cause side effects.
Especially tell your healthcare provider if you take central nervous system (CNS) depressants, psychostimulants, or monoamine oxidase inhibitors (MAOIs) medicine. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine.
How will I take SPRAVATO®?
What should I avoid while taking SPRAVATO®?
Do not drive, operate machinery, or do anything where you need to be completely alert after taking SPRAVATO®. Do not take part in these activities until the next day following a restful sleep. See “What is the most important information I should know about SPRAVATO®?”
What are the possible side effects of SPRAVATO®?
SPRAVATO® may cause serious side effects including:
See “What is the most important information I should know about SPRAVATO®?”
Increased blood pressure. SPRAVATO® can cause a temporary increase in your blood pressure that may last for about 4 hours after taking a dose. Your healthcare provider will check your blood pressure before taking SPRAVATO® and for at least 2 hours after you take SPRAVATO®. Tell your healthcare provider right away if you get chest pain, shortness of breath, sudden severe headache, change in vision, or seizures after taking SPRAVATO®.
Problems with thinking clearly. Tell your healthcare provider if you have problems thinking or remembering.
Bladder problems. Tell your healthcare provider if you develop trouble urinating, such as a frequent or urgent need to urinate, pain when urinating, or urinating frequently at night.
The most common side effects of SPRAVATO® include:
If these common side effects occur, they usually happen right after taking SPRAVATO® and go away the same day.
These are not all the possible side effects of SPRAVATO®.
Call your doctor for medical advice about side effects. You may report side effects to Johnson & Johnson at 1-800-526-7736, or to the FDA at 1-800-FDA-1088.
What is SPRAVATO® (esketamine) CIII nasal spray?
SPRAVATO® is a prescription medicine used:
SPRAVATO® is not for use as a medicine to prevent or relieve pain (anesthetic). It is not known if SPRAVATO® is safe or effective as an anesthetic medicine.
It is not known if SPRAVATO® is safe and effective for use in preventing suicide or in reducing suicidal thoughts or actions. SPRAVATO® is not for use in place of hospitalization if your healthcare provider determines that hospitalization is needed, even if improvement is experienced after the first dose of SPRAVATO®.
It is not known if SPRAVATO® is safe and effective in children.
Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.
All Rights Reserved | Greenbrook TMS NeuroHealth Centers.